RU94027342A - Antiteratogenic agent - Google Patents

Antiteratogenic agent

Info

Publication number
RU94027342A
RU94027342A RU94027342/14A RU94027342A RU94027342A RU 94027342 A RU94027342 A RU 94027342A RU 94027342/14 A RU94027342/14 A RU 94027342/14A RU 94027342 A RU94027342 A RU 94027342A RU 94027342 A RU94027342 A RU 94027342A
Authority
RU
Russia
Prior art keywords
teratogenic
agent
level
plant
lipid peroxidation
Prior art date
Application number
RU94027342/14A
Other languages
Russian (ru)
Other versions
RU2058786C1 (en
Inventor
А.М. Котин
Н.К. Бичевая
Original Assignee
А.М. Котин
Русско-Израильское совместное предприятие "Пренатальная безопасность"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by А.М. Котин, Русско-Израильское совместное предприятие "Пренатальная безопасность" filed Critical А.М. Котин
Priority to RU9494027342A priority Critical patent/RU2058786C1/en
Priority to PCT/RU1995/000146 priority patent/WO1996002266A1/en
Application granted granted Critical
Publication of RU2058786C1 publication Critical patent/RU2058786C1/en
Publication of RU94027342A publication Critical patent/RU94027342A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Botany (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

FIELD: medicine, pharmacy, plant preparations. SUBSTANCE: agent is biopreparation of the known cultured tissue of plant Poliascias filicifolia (from Araliaceae family). Preparation shows antioxidative property, it normalizes the damaged activities of catalase, superoxide dismutase, ceruleoplasmin, level of lipid peroxidation and also creatine kinase and isoforms of embryo brain enolase during fetus alcoholic syndrome development. EFFECT: enhanced antiembryotoxic level of antiteratogenic agent proposed. 6 tbl

Claims (1)

Изобретение относится к медицине, а именно - к производству лекарственных препаратов из растительного сырья, и может быть использовано в качестве антитератогенного фармакологического средства, снижающего или предотвращающего риск аномалий развития, индуцированных токсическими воздействиями, в частности, алкогольной интоксикацией в период беременности. Техническим результатом изобретения является обеспечение требуемого уровня противоэмбриотоксического эффекта антитератогенного средства на основе природных соединений по отношению к тератогенным воздействиям при расширении его сырьевой базы. Технический результат достигается применением биопрепарата известной культуры тканей растения Poliscias filicifolia (растительного адаптогена семейства аралиевых) в качестве антитератогенного средства. Обнаруженные у этого препарата антиоксидантные свойства, нормализующие нарушения активности ферментов антиоксидантной защиты: каталазы, супероксиддисмутазы, церулоплазмина, уровня ПОЛ (перикисного окисления липидов), а также ферментов энергетического обмена: креатинкиназы и изоформенолазы мозга эмбриона, при развитии алкогольного синдрома плода в сочетании с другими свойствами полисциас позволяют обеспечить необходимый противоэмбриотоксический уровень антитератогенного средства.The invention relates to medicine, namely to the production of medicines from plant materials, and can be used as an anti-teratogenic pharmacological agent that reduces or prevents the risk of developmental anomalies induced by toxic effects, in particular, alcohol intoxication during pregnancy. The technical result of the invention is to provide the required level of anti-embryotoxic effect of an anti-teratogenic agent based on natural compounds with respect to teratogenic effects while expanding its raw material base. The technical result is achieved by the use of a biological product of the known tissue culture of the plant Poliscias filicifolia (plant adaptogen of the aralia family) as an anti-teratogenic agent. The antioxidant properties found in this preparation normalizing impaired activity of antioxidant enzymes: catalase, superoxide dismutase, ceruloplasmin, the level of lipid peroxidation (lipid peroxidation), and energy metabolism enzymes: creatine kinase and isoformolase of the embryo’s brain, in the development of fetal alcohol syndrome in combination with other properties polysiasis allow you to provide the necessary anti-embryotoxic level of anti-teratogenic agents.
RU9494027342A 1994-07-15 1994-07-15 Antiteratogenic agent RU2058786C1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
RU9494027342A RU2058786C1 (en) 1994-07-15 1994-07-15 Antiteratogenic agent
PCT/RU1995/000146 WO1996002266A1 (en) 1994-07-15 1995-07-06 Anti-teratogenic agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU9494027342A RU2058786C1 (en) 1994-07-15 1994-07-15 Antiteratogenic agent

Publications (2)

Publication Number Publication Date
RU2058786C1 RU2058786C1 (en) 1996-04-27
RU94027342A true RU94027342A (en) 1996-08-27

Family

ID=20158738

Family Applications (1)

Application Number Title Priority Date Filing Date
RU9494027342A RU2058786C1 (en) 1994-07-15 1994-07-15 Antiteratogenic agent

Country Status (2)

Country Link
RU (1) RU2058786C1 (en)
WO (1) WO1996002266A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7071199B1 (en) 1999-09-17 2006-07-04 Abbott Gmbh & Cco. Kg Kinase inhibitors as therapeutic agents
RU2760674C1 (en) * 2020-07-06 2021-11-29 Общество с ограниченной ответственностью "Биофармокс" Use of preparations of polyscias filicifolia plant or its fragments for treatment of elementoses and their consequences

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5936621A (en) * 1982-08-25 1984-02-28 Tsumura Juntendo Inc Improving agent for cancerous symptom
US5225203C1 (en) * 1987-07-01 2001-05-15 Kim Won Kyq Son Pharmaceutical liquid composition containing bezoar bovis
WO1992021357A1 (en) * 1991-06-07 1992-12-10 Krewel-Werke Gmbh Concentrated and/or dry plant extracts
JPH04316448A (en) * 1991-04-12 1992-11-06 Iwatani Internatl Corp Production of carrot fine powder
JPH05960A (en) * 1991-06-19 1993-01-08 Kanebo Ltd Therapeutic agent for chronic fatigue syndrome
KR930012028A (en) * 1991-12-19 1993-07-20 박용성 Herbal Medicine

Also Published As

Publication number Publication date
RU2058786C1 (en) 1996-04-27
WO1996002266A1 (en) 1996-02-01

Similar Documents

Publication Publication Date Title
Reiter et al. Peripheral reproductive organ health and melatonin: ready for prime time
Iamsaard et al. Antioxidant activity and protective effect of Clitoria ternatea flower extract on testicular damage induced by ketoconazole in rats
Liu‐Snyder et al. Acrolein‐mediated mechanisms of neuronal death
Tvrdá et al. Resveratrol offers protection to oxidative stress induced by ferrous ascorbate in bovine spermatozoa
Kim et al. Preliminary report on the safety of a new herbal formula and its effect on sperm quality
BR9915247A (en) Biaromatic compounds analogous to vitamin D, their uses, pharmaceutical composition and cosmetic composition containing them, and use of cosmetic composition
PT88985A (en) Process for the preparation of nasal and ophthalmic pharmaceutical compositions containing azelastine
ES2174328T3 (en) SUBSTANCES WITH BIOLOGICAL ACTIVITY, ITS PROCESSING PROCEDURE AND THE COMPOSITIONS THAT INCLUDE THEM.
Zeka et al. New hydrogels enriched with antioxidants from saffron crocus can find applications in wound treatment and/or beautification
Sinex Biochemistry of Aging: The mechanism of aging presents a challenge to modern biochemistry and biology.
BR9704626A (en) Strained substances from dictyotales, process for their preparation and compositions that contain them.
Vora et al. Protective effects of Petroselinum crispum (Mill) Nyman ex AW Hill leaf extract on D-galactose-induced oxidative stress in mouse brain
Choi et al. Methamphetamine-induced apoptosis in a CNS-derived catecholaminergic cell line
RU94027342A (en) Antiteratogenic agent
ITRM970238A0 (en) USE OF THE NERVE GROWTH FACTOR IN THE PRESERVATION OF CORNEAS IN CULTURE, IN THE PRODUCTION OF CORNEAL AND CONJUNCTIVAL TISSUES IN VITRO AND IN THE THERAPY OF CORNEAL AND CONJUNCTIVAL DISEASES
McCulley et al. Collagenolytic activity in experimental herpes simplex keratitis
ANDERSON The localization of cytochrome c oxidase activity during mitochondrial specialization in spermiogenesis of prosobranch snails
Zeghir-Bouteldja et al. In vitro study of nitric oxide metabolites effects on human hydatid of Echinococcus granulosus
ES2168845T3 (en) COSMETIC COMPOSITION CONTAINING AN ACTIVE COMPONENT ABLE TO STIMULATE "IN VIVO" THE PRODUCTION OF INTERLEUQUINE 6 (IL-6) BY HUMAN KERATINOCITS.
Al-Turfi et al. Evaluation of the effect of alcoholic extract of Laurus nobilis leaves on blood biochemical parameters and histological changes in the liver and kidney among female Wistar rats treated with Depakene (Sodium Valproate).
IT1284571B1 (en) ANTI-CANCER COMPOSITION CONTAINING AN EMBRYONAL OR PREGNANT UTERUS EXTRACT AS THE ACTIVE SUBSTANCE AND RELATED PROCEDURE FOR PREPARATION
Cornells et al. In vitro cytotoxicity tests on cultured human skin fibroblasts to predict the irritation potential of surfactants
Narkhede et al. Attenuation of neuronal damage by gymnemic acid in experimentally induced cerebral ischemia in rats
Vargas-Villarreal et al. Activity of intracellular phospholipase A1 and A2 in Giardia lamblia
US9669064B2 (en) Method for anti-oxidation, inhibiting activity and/or expression of matrix metalloproteinase, and/or promoting expression of collagen using Ixora parviflora leaf extract